- InterView
- Restoring confidence post-Invossa incident was my priority
- by Kim, Jin-Gu Jan 10, 2024 05:42am
- “Even in the face of failure, do not worry. As the CEO of the company, I will take full responsibility for everything. We will engage in frequent communication. Once we reach a consensus after thorough discussions, I will bear responsibility for the outcome, regardless of the outcome.” In his inaugural speech in March of the previous year,
- InterView
- ‘RCC treatment should reflect international guidelines’
- by Son, Hyung-Min Jan 9, 2024 05:49am
- The treatment paradigm for renal cell carcinoma has been changing with the emergence of immuno-oncology drugs, but the latest practice guidelines for the disease are not being reflected in practice in Korea. In-Keun Park, Professor of Oncology at Seoul Asan Medical Center stressed how treatment options for patients with recurrent renal ce
- InterView
- Targeted cardiomyopathy drug, Camzyos effective in Asians
- by Son, Hyung-Min Dec 19, 2023 11:19am
- The first targeted treatment option for obstructive hypertrophic cardiomyopathy has finally emerged. Obstructive hypertrophic cardiomyopathy (oHCM) is a sub-classification of hypertrophic cardiomyopathy that is characterized by LV outflow tract (LVOT) obstruction impeding blood flow from the heart to the rest of the body. Previously, t
- InterView
- 'Janssen’s strong in autoimmune diseases for a reason'
- by Eo, Yun-Ho Dec 7, 2023 01:28pm
- Most pharmaceutical companies have one business unit that represents the company. These units, which usually own specialized cardiovascular, anticancer, or antiviral products, or have flagship products that lead their respective markets, are often revered within the company as well. Janssen Korea’s Immunology Business Unit is one such
- InterView
- ‘Leclaza can occupy 50% of mkt if used as combination'
- by Jung, Sae-Im Jul 28, 2023 05:30am
- Yuhan Corp’s Leclaza (lazertinib) was the first homegrown new drug to be approved as a first-line treatment for EGFR mutation-positive non-small-cell lung cancer. The industry’s eyes are now on how the drug will fare in the global market. Will Leclaza be able to rise as a new contender to AstraZeneca’s ‘Tagrisso (osimertinib)’ that is domin
- InterView
- Immunotherapy for early lung cancer was used
- by Jun 29, 2023 05:56am
- As immuno-anticancer drugs can be used in early lung cancer, the prognosis of patients is improving. Unlike before, when chemotherapy and concurrent chemoradiation were all, it is evaluated that the number of cases of 'complete pathological remission' has increased. Opdivo was approved by the Ministry of Food and Drug Safety in October of last y
- InterView
- The use of HTN combi tx in Korea is the highest in the world
- by May 23, 2023 05:53am
- Korea is the best in the world for complex drugs related to hypertension and hyperlipidemia. The drugs prescribed for each patient’s condition will change, but recently there is a growing trend to use complex drugs that are convenient to take.” Park Chang-gyu, chairman of the Society for Hypertension (Professor, Cardiovascular Center, Kor
- InterView
- ‘Even a 0.2 vision is a miracle to some’
- by Eo, Yun-Ho May 15, 2023 05:41am
- The reason for the slow development of new drugs in a specific disease can usually be attributed to one of the following two reasons. Low disease awareness or difficulty in developing the drug itself. The one-shot gene therapy Novatis’s ‘Luxturna (voretigene neparvovec)’ is a drug that overcame both barriers. Luxturna, which is a treat
- InterView
- Samsung Bio, investing in Swiss ADC bio company
- by Hwang, Jin-joon Apr 13, 2023 05:43am
- Samsung Biologics announced on the 12th that it invested in Araris Biotech AG through the 'Samsung Life Science Fund' along with Samsung C&T. This investment was conducted exclusively by Samsung as a strategic investor (SI) prior to Araris Biotech AG's Series A phase. The investment is expected to be used for the further development of an
- InterView
- CDK4/6 latecomer Kisqali exudes confidence in its effect
- by Jung, Sae-Im Apr 11, 2023 06:11am
- Novartis’s Kisqali (rivociclib), a latecomer CDK4/6 inhibitor used in metastatic breast cancer, is taking on an unexplored path, away from other CDK4/6 inhibitors. The drug has demonstrated efficacy in aggressive forms of breast cancer, which had not been attempted by other CDK 4/6 inhibitors. Aggressive breast cancers appear relatively often i
